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AbstrACt
background Chronic subdural hematoma (CSDH) is a 
common neurological condition; surgical evacuation is the 
mainstay of treatment for symptomatic patients. No clear 
evidence exists regarding the impact of timing of surgery 
on outcomes. We investigated factors influencing time to 
surgery and its impact on outcomes of interest.
Methods Patients with CSDH who underwent burr- hole 
craniostomy were included. This is a subset of data from 
a prospective observational study conducted in the UK. 
Logistic mixed modelling was performed to examine the 
factors influencing time to surgery. The impact of time 
to surgery on discharge modified Rankin Scale (mRS), 
complications, recurrence, length of stay and survival was 
investigated with multivariable logistic regression analysis.
results 656 patients were included. Time to surgery 
ranged from 0 to 44 days (median 1, IQR 1–3). Older age, 
more favorable mRS on admission, high preoperative 
Glasgow Coma Scale score, use of antiplatelet 
medications, comorbidities and bilateral hematomas were 
associated with increased time to surgery. Time to surgery 
showed a significant positive association with length of 
stay; it was not associated with outcome, complication 
rate, reoperation rate, or survival on multivariable analysis. 
There was a trend for patients with time to surgery of ≥7 
days to have lower odds of favorable outcome at discharge 
(p=0.061).
Conclusions This study provides evidence that time 
to surgery does not substantially impact on outcomes 
following CSDH. However, increasing time to surgery is 
associated with increasing length of stay. These results 
should not encourage delaying operations for patients 
when they are clinically indicated.
IntroduCtIon
Chronic subdural hematoma (CSDH) is a 
common neurosurgical condition, resulting 
from the formation of liquefied blood in the 
subdural space between the dura and arach-
noid mater, usually following trivial trauma. 
Occurring in up to 14 per 100 000 people 
per year, the mainstay of treatment for symp-
tomatic CSDH is surgical evacuation. Patients 
with CSDH are typically elderly, with a high 
incidence of comorbidities and iatrogenic 
coagulopathy and thrombopathy.1 Often, 
there are practical reasons for delaying 
surgery in symptomatic patients; for example, 
the British Society of Haematology recom-
mends delaying surgery until 24 hours after 
the last dose of direct oral anticoagulants, 
extended to 48 hours if the patient has renal 
impairment or is on a direct thrombin inhib-
itor.2 For other patients, delays may result 
from non- evidence- based decision- making 
and logistical issues within health services.
The timing of neurosurgical intervention in 
CSDH is relatively understudied, with no high- 
quality evidence regarding the optimal time 
to intervene. Studies of patients with acute 
traumatic extra- axial hematomas have previ-
ously demonstrated an improved outcome 
with surgical intervention within 4 hours of 
injury but these findings cannot be directly 
translated to CSDH, as the pathophysiology 
and clinical presentation of the latter differs 
Key messages
What is already known about this subject?
 ► Chronic subdural hematoma is a common condition.
 ► Surgical evacuation of the hematoma is often the 
treatment.
 ► Elderly patients are commonly affected.
What are the new findings?
 ► Factors associated with longer time to surgery were 
older age, antiplatelet medication use, low modified 
Rankin Scale on admission.
 ► There is a positive association between time to sur-
gery and length of stay.
How might these results affect future 
research or surgical practice?
 ► Our results emphasize the need to base time to sur-
gery decisions on clinical assessment. Further re-
search is required to explore this topic fully.
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significantly from the former.3 4 Additionally, more recent 
studies have challenged the ‘four hours’ rule.5 6 Most 
recently, a large UK study of patients with acute subdural 
hematoma found no evidence of an effect of time interval 
from injury to craniotomy (n=2498 patients, p=0.4203).7
The management of CSDH was recently investigated 
through a prospective, multicenter, observational cohort 
study in the UK.8 9 Variables associated with a favorable 
outcome included lower age, better initial modified 
Rankin Scale (mRS) score, higher preoperative Glasgow 
Coma Scale (GCS) score, using more than one burr- hole, 
inserting a subdural drain and avoiding prescribed bed 
rest. In the context of the outstanding research questions 
regarding timing of surgery and the above findings, this 
post hoc analysis aims to investigate (1) factors associated 
with time to surgery and (2) the impact of time to surgery 
on functional outcome, complications, recurrence, 
length of stay, and survival.
MetHods
Data were collected prospectively as described in the 
primary study publication and protocol.8 9 The main 
study protocol was approved by the Academic Committee 
of the Society of British Neurological Surgeons (SBNS). 
The study was supported by the SBNS and formed part 
of the Neurosurgical National Audit Program. Local 
governance approvals were in place in each participating 
neurosurgical unit. Data for 1205 patients referred to 
26 of the 33 UK and Ireland neurosurgical units were 
prospectively collected between May 2013 and January 
2014. This paper examined a subset of this sample, 
excluding patients (1) not transferred to a neurosurgical 
unit, (2) with a previous history of ipsilateral CSDH, (3) 
who did not have burr- hole evacuation, (4) with unavail-
able time to surgery data and (5) with a cerebrospinal 
fluid shunt. This paper is reported in accordance with the 
Strengthening the Reporting of Observational Studies in 
Epidemiology statement for cohort studies.10
Time from neurosurgical referral to surgery was cate-
gorized as follows: 0, 1, 2, 3–6, and 7 or more days. The 
time interval was calculated by subtracting the date of 
referral from date of operation (specific times in hours 
were not available). For example, a patient referred on 
1 December and operated on 1, would be categorized as 
‘time to surgery 0 days’. A patient referred on 1 December 
and operated on the 2 would be categorized as ‘time 
to surgery 1 day’. Univariable categorical comparisons 
on pair- wise data were undertaken using Fisher’s exact 
testing. Comparisons of continuous data were under-
taken using Kruskal- Wallis testing.
We performed mixed modelling as a logistic model 
to examine factors influencing time to surgery. In this 
model, time to surgery was the dependent variable, with 
a cut- off for early surgical intervention based on the 
median of data collected and data distribution. Indepen-
dent variables were selected based on clinical relevance 
and included if found to be significant (p<0.05) with 
concomitant improvement in the model, as demonstrated 
by the Akaike Information Criterion (AIC) under multi-
variable analysis.11 The neurosurgical center was included 
as a random effect due to hypothesized differences in 
median time to surgery and heterogeneous sampling 
between centers.
Time to surgery was modelled as a categorical, indepen-
dent variable to evaluate its impact on (1) discharge mRS, 
expressed as either favorable (0–3) or unfavorable (4–6), 
(2) complications, which included surgical site infection, 
seizures, new deficits, respiratory tract infections, arrhyth-
mias, venous thromboembolism, myocardial infarctions 
and cerebrovascular accidents, (3) symptomatic recur-
rence requiring repeat surgery, (4) length of stay, and 
(5) survival. Time to surgery was categorized as described 
above. Each time interval category was compared with 0 
days for the calculation of ORs. Covariates were selected 
based on the results of the logistic mixed modelling and 
in accordance with previously published models of these 
data, including patient age as a continuous variable, 
initial mRS and preoperative GCS as ordinal variables, 
and antiplatelet medication, clot density, 2 or more burr- 
holes, bilateral operation, drain insertion, management 
with bed rest and provision of high- flow oxygen as dichot-
omous variables. Results were not repeated if consistent 
with previously published material.8
Logistic mixed modelling and regression analyses were 
performed using rms and lme4 packages in R v 3.2.1.12 13 
A single p value was obtained by computing a Wald χ2 
pooled statistic of all coefficients of the variable of interest 
and was significant if p<0.05. All descriptive graphics were 
completed using the ggplot2 package in R 3.2.1.14
results
Of the 1205 patients examined, 656 patients met the 
inclusion criteria for this study. These patients all had a 
primary unilateral or bilateral CSDH (in the absence of a 
shunt) drained via burr- holes in a participating neurosur-
gical unit (figure 1). Time to surgery ranged from 0 to 44 
days, with a median of 1 day and IQR of 1–3 days for the 
overall sample. Distribution of patients according to time 
to surgery is shown in table 1.
Descriptive statistics are presented in table 1 and 
figure 2. Of the patients with severe neurological impair-
ment, defined by a preoperative GCS of <9, 11 out of 13 
(85%) received burr- hole evacuation within 1 day following 
referral. Older patients were more likely to undergo an 
operation at a later stage, with a median age of 76 years 
for patients operated on the same day as the referral (ie, 0 
days) compared with 80 years for patients operated at 7 or 
more days (p=0.019). A larger proportion of patients oper-
ated on 7 or more days after referral were taking antiplatelet 
medication compared with those operated on at 0 days 
(n=29/78, 38% vs n=29/133, 22%, p=0.017). This effect 
was less pronounced with warfarin, with a similar propor-
tion of patients (n=18/133, 14% of patients) operated on 0 
or 1 days versus 7 or more days (n=15/78, 19%; p=0.327). 
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Figure 1 Flow diagram of included patients. CSDH, chronic 
subdural hematoma.
Table 1 Summary demographics of patients (n=656)
Measure Statistic
Age (years, median, IQR) 78 (67–84)
Male (n, %) 449 (68)
Female (n, %) 207 (32)
Initial GCS (median, IQR) 14 (14–15)
  Mild impairment (13–15, n, %) 540 (82)
  Moderate impairment (9–12, n, %) 103 (16)
  Severe impairment (3–8, n, %) 13 (2)
Comorbidities (n, %)
  Diabetes mellitus 109 (17)
  Dementia 73 (11)
  COPD 36 (5)
  IHD 169 (26)
  CVA 103 (16)
  Malignancy 55 (8)
Anticoagulation (n, %)
  Warfarin use 124 (19)
  Antiplatelet medication use 157 (24)
Initial mRS (median, IQR) 3 (2–4)
Length of stay (days, median, IQR) 7 (5–12)
Recollection / reoperation within 60 days (n, 
%)
59 (9)
Patients in each time to surgery (days) category (n, %)
  0 days 133 (20)
  1 day 241 (37)
  2 days 104 (16)
  3–6 days 100 (15)
  7+ days 78 (12)
COPD, Chronic obstuctive pulmonary disease; CVA, 
Cerebrovascular accident; GCS, Glasgow Coma Scale; IHD, 
Ischaemic heart disease ; mRS, modified Rankin Scale.
Distribution of patients across time to surgery categories 
differed between neurosurgical centers (figure 3). Patients 
were most commonly operated on between 0 and 2 days 
after referral in 21 neurosurgical centers. Three centers 
submitted cohorts with a median time from referral to 
surgery of 3 or more days.
Factors influencing time to surgery
Mixed modelling results are shown in table 2. Time to 
surgery was modelled, based on a median value of 1 day, 
into ‘early’ if ≤1 day (n=374/656, 57.0%) or ‘late’ if ≥2 
days (n=282/656, 43.0%). Other variables included 
age, initial mRS, preoperative GCS, use of antiplatelet 
medication, number of comorbidities and whether the 
CSDH was bilateral. The inclusion of the neurosurgical 
center significantly improved the model fit (AIC 867.8 as 
logistic regression vs 838.8 as generalized mixed model).
The following variables were associated with a longer 
time to surgery: increasing age (OR 1.02 (95% CI 1.00 to 
1.03), p=0.008), higher preoperative GCS (OR 1.19 (95% 
CI 1.06 to 1.32), p=0.002), higher number of comorbid-
ities (OR 1.38 (95% CI 1.15 to 1.66), p<0.001), and the 
use of antiplatelet medications (OR 1.61 (95% CI 1.07 to 
2.42), p=0.022). Conversely, a shorter time to surgery was 
associated with a higher admission mRS (OR 0.84 (95% 
CI 0.71 to 0.99), p=0.034) and the evacuation of a unilat-
eral CSDH (OR 0.64 (95% CI 0.43 to 0.96), p=0.029).
Variables excluded from the model that were not 
significant and did not improve model fit included sex 
(p=0.527), preoperative use of warfarin (p=0.6757), and 
preoperative requirements of platelets (p=0.184), fresh 
Edinburgh. Protected by copyright.
 o
n
 D
ecem
ber 17, 2019 at University of
http://sit.bmj.com/
BM
J Surg Interv Health Technologies: first published as 10.1136/bmjsit-2019-000012 on 15 December 2019. Downloaded from 
4 Venturini S, et al. BMJ Surg Interv Health Technologies 2019;1:e000012. doi:10.1136/bmjsit-2019-000012
Open access 
Figure 2 Distribution of patients by time to surgery, stratified by risk factor with absolute numbers and proportions by time 
category shown. GCS, Glasgow Coma Scale.
frozen plasma (p=0.550), vitamin K (p=0.951), or clotting 
factors (p=0.170). Tested interaction terms (between age, 
initial mRS and comorbidities and between presence of 
bilateral CSDH and preoperative GCS) were not found to 
be significant.
Impact of time to surgery on outcomes of interest
Logistic regression results across the five dependent vari-
ables of interest are shown in figure 4. Number of comor-
bidities was included alongside previously published 
variables in the multivariable model (see covariates for 
further details in the Methods section).
All comparisons of the various time intervals to surgery 
compared with 0 days were not found to be significantly 
related to a favorable outcome at discharge (p=0.061–
0.837), rate of complications (n=88, p=0.428–0.957), 
rate of postoperative recollection requiring reoperation 
(n=59, p=0.075–0.454) or survival (n=11, p=0.367–0.948). 
Nevertheless, there was a trend indicating that a time 
interval of 7 days or more had lower odds of favorable 
outcome at discharge (p=0.061). Time to surgery was 
significantly associated with length of stay dichotomized 
based on a median of 7 days, with an increasing time to 
surgery associated with a greater length of stay (time to 
surgery 3–6 days OR 2.79 (95% CI 1.53 to 5.09), p=0.001, 
7+ days OR 3.91 (95% CI 2.03 to 7.54), p<0.001, figure 4). 
Other variables significantly associated with length of stay 
included initial mRS (OR 1.88 (95% CI 1.39 to 2.55), 
p<0.001) and postoperative high- flow oxygen (OR 0.50 
(95% CI 0.27 to 0.94), p=0.030).
dIsCussIon
Given the lack of definitive evidence available in the liter-
ature, there is uncertainty over the impact of the timing 
of surgery for CSDH on outcome. This observational 
cohort study, involving 656 patients with CSDH, inves-
tigated whether the time interval between referral and 
surgery impacted on functional outcome at discharge 
(mRS), complication rates, recurrence requiring reoper-
ation, length of stay, and survival. While there was varia-
tion between units, the median time to surgery was 1 day, 
so in general it appears that most patients receive surgery 
in a timely manner.
Time to surgery demonstrated a positive linear rela-
tionship with length of stay. We found that a number 
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Figure 3 Distribution of patients by time to surgery stratified 
by neurosurgical center.
Table 2 Mixed model results of time to surgery
Variable Estimate SE Z Pr(>|z|) OR (95% CI)
Age 0.019 0.007 2.661 0.008 1.02 (1.00 to 1.03)
Initial mRS −0.178 0.084 −2.109 0.034 0.84 (0.71 to 0.99)
Preoperative GCS 0.172 0.056 3.067 0.002 1.19 (1.06 to 1.32)
Antiplatelet medications=yes 0.477 0.208 2.287 0.022 1.61 (1.07 to 2.42)
No of comorbidities 0.324 0.094 3.454 <0.001 1.38 (1.15 to 1.66)
CSDH=unilateral only −0.445 0.204 −2.177 0.029 0.64 (0.43 to 0.96)
CSDH, chronic subdural hematoma; GCS, Glasgow Coma Scale; mRS, modified Rankin Scale.
of variables were associated with a longer time interval 
between referral and surgical intervention. These 
included increasing patient age, lower mRS, higher GCS, 
use of antiplatelet agents, presence of comorbidities, and 
presence of bilateral CSDH (p<0.05 for all variables).
Although interactions between age and comorbidities 
were tested and not found to be significant when building 
the model for this study, large epidemiological studies 
have demonstrated increasing comorbidities with age.15 16 
Published reports by the National Confidential Enquiry 
into Patient Outcome and Death have highlighted the 
importance of multidisciplinary decision- making in 
surgery in the elderly where there is an increased risk of 
perioperative morbidity and mortality.17 Integrated care 
pathways have been effectively developed in Trauma and 
Orthopaedics for patients with a fractured neck of femur, 
with best practice tariffs if the patient is admitted under 
the joint care of a consultant orthopedic surgeon and a 
consultant geriatrician, and is postoperatively cared for 
by a geriatrician- directed multiprofessional rehabilitation 
team.18 Such pathways and systemic incentives have only 
recently started to be developed for elderly patients with 
CSDH, and seem to show early promising results including 
better preoperative optimization of patients.19 20
As antiplatelet agents are usually stopped prior to 
surgery, it is common practice to delay surgery for 5-10 
days, depending on the agent, or transfuse platelets if 
surgery needs to be undertaken on an urgent basis.21 22 
Notably, class III evidence demonstrates that waiting 3 
days is sufficient to proceed to surgery after cessation of 
antiplatelet therapy with no recurrence after this time 
point.23
Evidence that time to surgery does not have a substan-
tial adverse impact on clinical outcomes, as suggested in 
this study, could allay pressure from the managing team 
and encourage optimization for surgery. Our findings are 
in line with those of a recent retrospective cohort study 
from Sweden showing that increased time from CT scan 
to surgical evacuation for CSDH did not negatively impact 
outcomes, when surgery was performed within a clinically 
appropriate time frame.24 It appears that patients at risk 
of deterioration or those who are neurologically impaired 
are already being prioritized, as we found that a more 
unfavorable initial mRS, and lower GCS were associated 
with a shorter time to surgery. It would be ideal for the 
patient to undergo surgery as soon as practically feasible 
to begin the process of recovery and resolution of defi-
cit(s), and we advocate for this to remain the ultimate 
aim in clinical practice. However, this has to be weighed 
against the importance of comprehensive preoperative 
assessment and optimization.
The trend between a time interval of 7 days or more 
and unfavorable outcome at discharge means that one 
cannot completely rule out a relationship between 
increasing time to surgery and worse functional outcome 
at discharge. Due to a paucity of studies in this field and 
risk of a type II error, further research should be carried 
out to investigate this potential relationship. We believe 
that decisions on when to intervene should always be 
guided by clinical assessment and the patient’s condition. 
When interpreting the results of this study, it must be 
remembered that this was an observational study without 
any randomization. Therefore, residual confounding and 
confounding by indication may still exist.
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Figure 4 Multivariable logistic regression statistical results. Variables are shown with ORs, 95% CIs and p values labeled 
beneath each variable. Time to surgery is reported relative to an interval of 0 days. Discharge mRS was dichotomized into 
favorable as 1 (representing mRS of 0–3) or unfavorable of 0 (representing mRS of 4–6). Length of stay was dichotomized based 
on a median length of stay for the cohort of 7 days. mRS, modified Rankin Scale.
The linear relationship between time to surgery and 
length of stay has important service provision implica-
tions. The management of CSDH already represents a 
significant burden to neurosurgical service provision, with 
an estimated incidence of 8.2/100 000/year after 70 years 
of age.25 This is expected to increase in the context of 
increasing use of antiplatelet and anticoagulant therapy 
in an aging population.26 There are broader implications, 
with head- injured patients representing a significant 
source of financial deficits for healthcare organizations 
in the UK.27 Consequently, there is an important consid-
eration to optimize neurosurgical service provision by 
reducing the length of stay for patients with CSDH. There 
is also limited evidence to suggest an increased length of 
stay is associated with a worse prognosis in CSDH.28
limitations and future work
Time to surgery was determined based on the time point 
of referral to neurosurgical services; a study looking at the 
time from the onset of neurological deterioration (eg, 
onset of hemiparesis) or time from diagnosis (CT scan) 
to surgery would be interesting, but these data were not 
available. Other pertinent data not available included the 
time of day the surgery was completed and whether or 
not the patient required a planned or unplanned admis-
sion to an intensive care unit. Discharge data also did not 
specify how long the patient remained in another hospital, 
such that overall in- hospital length of stay postoperatively 
could not be determined. Only patients undergoing burr- 
hole evacuation were included; however, this is the most 
common surgical procedure used to treat CSDH in the 
UK.8 29 It would be important to consider whether our 
findings are applicable to other patient groups such as 
those undergoing different procedures. Additionally, it 
would be important to establish whether risk stratification 
should be used when prioritizing patients for surgery.
Although this is a large sample of 656 patients, there is 
a risk of a type II error particularly given the conclusions 
derived from this study. This is exacerbated by selection 
bias due to the individual surgeon decision- making on 
optimal timing of surgery. The outcomes investigated were 
relatively short- term, with four out of five being assessed 
at discharge. The median length of stay in neurosurgical 
units was 7 days in the original study.8 The outcome with 
the longest follow- up time was recurrence rate, which was 
assessed for 60 days postoperatively; evidence suggests this 
is the highest risk time window and thereafter the risk of 
recurrence reduces.30 Conclusions about the longer- term 
outcome cannot be drawn at this stage. There is scope 
to expand this in further studies to lengthen follow- up 
to 6 months or longer. This would be helpful to under-
stand the disease progression and impact on function,31 
especially since previous studies highlighted that CSDH is 
comparable to hip fracture as a sentinel event for under-
lying systemic pathology with increased 1 year mortality.31 
32 This is particularly relevant for an elderly patient 
group; in this context, 6 month or 1 year outcomes are 
useful tools when completing holistic/comprehensive 
assessments. Additionally, complications following CSDH 
could be further classified into mild, moderate and severe 
groups based on clinical relevance, to ascertain if any of 
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these groups are affected individually, as described in a 
recent population- based study investigating predictors of 
recurrence and complications following CSDH.33 This was 
not possible in this paper, as such data were not collected.
Despite its limitations, this is a large UK wide study 
including 656 patients treated across 26 neurosurgical 
centers. Therefore, it is likely to be representative of 
current UK neurosurgical practice. As previously stated, 
whether timeliness of surgical intervention in CSDH 
has an impact on patient outcome has not been studied 
widely, and uncertainty remains. This study adds to the 
existing knowledge and prompts a new set of questions. 
The findings of the study apply to a state- funded health 
system where universal health coverage is provided, and 
therefore the conclusions may not necessarily be general-
izable to different healthcare systems.
Although our study did not evaluate a specific novel 
intervention, it is still useful to classify it according to the 
IDEAL (Idea, Development, Exploration, Assessment, 
Long- term study) framework.34 It can be viewed as an 
IDEAL stage 2b study, as exploratory analyses published as 
part of the primary paper8 identified a number of modifi-
able factors associated with better outcome, including use 
of two burr- holes and early mobilization. These are now 
being considered for evaluation with an IDEAL stage 3 
study. Additionally, it can be viewed as an IDEAL stage 4 
study with regards to the use of subdural drains, an inter-
vention which was found to be beneficial in a previous 
high- quality randomized controlled trial.35 Our prospec-
tive, multicenter, observational study demonstrated that 
the national recurrence rate was 9%, very similar to that 
observed in the drain arm of the aforementioned trial. 
More importantly, the multivariate analysis showed that 
not using a drain independently predicted recurrence 
and unfavorable functional outcome, validating the effec-
tiveness of subdural drains in a real- world setting.
ConClusIons
We have established that the current median time from 
referral to surgery is 1 day. The results do not demon-
strate a relationship between time to surgery and clinical 
outcome following CSDH, although we cannot completely 
rule out a relationship between increasing time to surgery 
and worse outcome at discharge. In line with currently 
accepted best practice, all patients should be operated on 
in a timely manner and as soon as possible where there 
are clinical indications for surgery. Increasing time to 
surgery was associated with a longer length of stay; this 
has important service delivery implications. With this in 
mind, it is now important to conduct further research to 
(1) establish whether a pathway focusing on timely surgery 
with adequate preoperative optimization can improve 
outcomes, (2) implement longer follow- up times, and (3) 
validate our results.
Author affiliations
1Department of Neurosurgery, Aberdeen Royal Infirmary, Aberdeen, UK
2Division of Neurosurgery, Department of Clinical Neurosciences, University of 
Cambridge & Addenbrooke's Hospital, Cambridge, UK
3Department of Neurosurgery, Queen's Medical Centre, Nottingham, UK
4Department of Neurosurgery, John Radcliffe Hospital, Oxford, UK
5Department of Neurosurgery, Royal Victoria Infirmary, Newcastle upon Tyne, UK
6Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation 
Trust, Cambridge, UK
7Department of Anaesthesia, Addenbrooke's Hospital, Cambridge, UK
8Translational Neurosurgery, Centre for Clinical Brain Sciences, The University of 
Edinburgh, Edinburgh, UK
twitter Angelos G Kolias @ag_kolias
Acknowledgements PJH is supported by a Research Professorship from the 
National Institute for Health Research (NIHR), the NIHR Cambridge Biomedical 
Research Centre, the NIHR Global Health Research Group on Neurotrauma, a 
European Union Seventh Framework Program grant (CENTER- TBI; grant no 
602150), and the Royal College of Surgeons of England. AGK is supported by a 
Clinical Lectureship, School of Clinical Medicine, University of Cambridge and the 
Royal College of Surgeons of England.   We thank the academic committee and the 
council of the Society of the British Neurological Surgeons for supporting the study.
Collaborators The following acted as investigators and should be cited on PubMed 
as collaborators (The British Neurosurgical Trainee Research Collaborative (BNTRC)): 
F T Afshari, A I Ahmed, A Alli, R Al- Mahfoudh, J Bal, A Belli, A Borg, D Bulters, N 
Carleton- Bland, A Chari, D Coope, C J Cowie, G Critchley, S Dambatta, D D’Aquino, 
B Dhamija, G Dobson, M D Fam, L Glancz, W P Gray, B A Gregson, P Grover, J 
Halliday, A Hamdan, C S Hill, A A B Jamjoom, A Joannides, T L Jones, S M Joshi, A 
Kailaya- Vasan, V Karavasili, S A Khan, A T King, A Kuenzel, L J Livermore, W Lo, H 
Marcus, J Martin, S Matloob, P Mitchell, D Mowle, H Narayanamurthy, R J Nelson, D 
Ngoga, I Noorani, G O’Reilly, H Othman, K Owusu- Agyemang, K S Manjunath Prasad, 
P Plaha, J Pollock, M T C Poon, K S Prasad, R Price, C Pringle, A Ray, J Reaper, W 
Scotton, J Shapey, N Simms, S Smith, P Statham, L Steele, J St George, M G Stovell, 
A Tarnaris, M Teo, S Thomson, L Thorne, M Vintu, P Whitfield, M Wilson, M Wilby, J 
Woodfield, M Zaben.
Contributors Conception of the study: DMF, ICC, PJH, PMB, AGK. Analysis and 
interpretation: DMF, SV, LJG, LJL, SB, BM, PJH, PMB, AGK. Data acquisition: LJG, 
LJL, ICC, PMB, AGK. Drafting manuscript: DMF, SV, AGK. Revising critically the 
manuscript: DMF, SV, LJG, LJL, ICC, SB, BM, PJH, PMB, AGK.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
orCId id
Angelos G Kolias http:// orcid. org/ 0000- 0003- 3992- 0587
reFerenCes
 1 Kolias AG, Chari A, Santarius T, et al. Chronic subdural haematoma: 
modern management and emerging therapies. Nat Rev Neurol 
2014;10:570–8.
 2 Keeling D, Tait RC, Watson H, et al. Peri- Operative management 
of anticoagulation and antiplatelet therapy. Br J Haematol 
2016;175:602–13.
 3 Seelig JM, Becker DP, Miller JD, et al. Traumatic acute subdural 
hematoma: major mortality reduction in comatose patients treated 
within four hours. N Engl J Med 1981;304:1511–8.
 4 England. Trc of S of. Report of the Working Party on the management 
of patients with head injuries. London: R Coll Surg England, 1999.
 5 Dent DL, Croce MA, Menke PG, et al. Prognostic factors after acute 
subdural hematoma. J Trauma 1995;39:36–43. Discussion 42-3.
Edinburgh. Protected by copyright.
 o
n
 D
ecem
ber 17, 2019 at University of
http://sit.bmj.com/
BM
J Surg Interv Health Technologies: first published as 10.1136/bmjsit-2019-000012 on 15 December 2019. Downloaded from 
8 Venturini S, et al. BMJ Surg Interv Health Technologies 2019;1:e000012. doi:10.1136/bmjsit-2019-000012
Open access 
 6 Tien HCN, Jung V, Pinto R, et al. Reducing Time- to- Treatment 
decreases mortality of trauma patients with acute subdural 
hematoma. Ann Surg 2011;253:1178–83.
 7 Fountain DM, Kolias AG, Lecky FE, et al. Survival trends after surgery 
for acute subdural hematoma in adults over a 20- year period. Ann 
Surg 2017;265:590–6.
 8 Brennan PM, Kolias AG, Joannides AJ, et al. The management 
and outcome for patients with chronic subdural hematoma: a 
prospective, multicenter, observational cohort study in the United 
Kingdom. J Neurosurg 2017;127:732–9.
 9 Coulter IC, Kolias AG, Marcus HJ, et al. Proposal for a prospective 
multi- centre audit of chronic subdural haematoma management in 
the United Kingdom and ireland. Br J Neurosurg 2014;28:199–203.
 10 von Elm E, Altman DG, Egger M, et al. The strengthening the 
reporting of observational studies in epidemiology (STROBE) 
statement: guidelines for reporting observational studies. The Lancet 
2007;370:1453–7.
 11 Akaike H. Information theory and an extension of the maximum 
likelihood principle. in. New York, NY: Springer, 1998: 199–213.
 12 HarrellF. Rms: regression modeling strategies. R package version 
4.2-1, 2014. Available: https:// cran. r- project. org/ web/ packages/ rms/ 
index. html [Accessed 25 Apr 2019].
 13 Bates D, Mächler M, Bolker B, et al. Fitting Linear Mixed- Effects 
Models Using lme4. J Stat Softw 2015;67:1–48.
 14 Wickham H. Ggplot2 : Elegant Graphics for Data Analysis. Springer, 
2009.
 15 Barnett K, Mercer SW, Norbury M, et al. Epidemiology of 
multimorbidity and implications for health care, research, 
and medical education: a cross- sectional study. The Lancet 
2012;380:37–43.
 16 Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and 
complications of multiple chronic conditions in the elderly. Arch 
Intern Med 2002;162:2269–76.
 17 National confidential enquiry into patient outcome and death. 
Available: https://www. ncepod. org. uk/ publications. html
 18 Nhs improvement website. Available: https:// improvement. nhs. uk/ 
resources/
 19 Shapey J, Glancz LJ, Brennan PM. Chronic subdural haematoma in 
the elderly: is it time for a new paradigm in management? Curr Geri 
Rep 2016;5:71–7.
 20 Bapat S, Shapey J, Toma A, et al. Chronic subdural haematomas: a 
single- centre experience developing an integrated care pathway. Br J 
Neurosurg 2017;31:434–8.
 21 Korinth MC. Low- Dose aspirin before intracranial surgery – results 
of a survey among neurosurgeons in Germany. Acta Neurochir 
2006;148:1189–96.
 22 Poon MTC, Rea C, Kolias AG, et al. Influence of antiplatelet 
and anticoagulant drug use on outcomes after chronic subdural 
hematoma drainage. J Neurotrauma 2019. doi:10.1089/
neu.2018.6080. [Epub ahead of print: 30 Jan 2019].
 23 Wada M, Yamakami I, Higuchi Y, et al. Influence of antiplatelet 
therapy on postoperative recurrence of chronic subdural hematoma: 
a multicenter retrospective study in 719 patients. Clin Neurol 
Neurosurg 2014;120:49–54.
 24 Zolfaghari S, Ståhl N, Nittby Redebrandt H. Does time from 
diagnostic CT until surgical evacuation affect outcome in 
patients with chronic subdural hematoma? Acta Neurochir 
2018;160:1703–9.
 25 Asghar M, Adhiyaman V, Greenway MW, et al. Chronic subdural 
haematoma in the elderly--a North Wales experience. J R Soc Med 
2002;95:290–2.
 26 Santarius T, Kirkpatrick PJ, Kolias AG, et al. Working toward rational 
and evidence- based treatment of chronic subdural hematoma. Clin 
Neurosurg 2010;57:112–22.
 27 Fountain DM, Kolias AG, Laing RJ, et al. The financial outcome 
of traumatic brain injury: a single centre study. Br J Neurosurg 
2017;31:350–5.
 28 Hussain R, Afzal M, Joshi S, et al. Factors affecting the survival 
following surgical treatment of chronic subdural haematoma: single 
institutional experience. J Clin Neurosci 2017;44:75–9.
 29 Almenawer SA, Farrokhyar F, Hong C, et al. Chronic subdural 
hematoma management: a systematic review and meta- analysis of 
34,829 patients. Ann Surg 2014;259:449–57.
 30 Mori K, Maeda M. Surgical treatment of chronic subdural hematoma 
in 500 consecutive cases: clinical characteristics, surgical 
outcome, complications, and recurrence rate. Neurol Med Chir 
2001;41:371–81.
 31 Leroy H- A, Aboukaïs R, Reyns N, et al. Predictors of functional 
outcomes and recurrence of chronic subdural hematomas. J Clin 
Neurosci 2015;22:1895–900.
 32 Miranda LB, Braxton E, Hobbs J, et al. Chronic subdural hematoma 
in the elderly: not a benign disease. J Neurosurg 2011;114:72–6.
 33 Bartek J, Sjåvik K, Kristiansson H, et al. Predictors of recurrence 
and complications after chronic subdural hematoma surgery: a 
population- based study. World Neurosurg 2017;106:609–14.
 34 Hirst A, Philippou Y, Blazeby J, et al. No surgical innovation without 
evaluation: evolution and further development of the ideal framework 
and recommendations. Ann Surg 2019;269:211–20.
 35 Santarius T, Kirkpatrick PJ, Ganesan D, et al. Use of drains 
versus no drains after burr- hole evacuation of chronic 
subdural haematoma: a randomised controlled trial. Lancet 
2009;374:1067–73.
Edinburgh. Protected by copyright.
 o
n
 D
ecem
ber 17, 2019 at University of
http://sit.bmj.com/
BM
J Surg Interv Health Technologies: first published as 10.1136/bmjsit-2019-000012 on 15 December 2019. Downloaded from 
